TB and HIV Therapeutics: Pharmacology Research Priorities by Kelly E. Dooley, Peter S. Kim, Sharon D. Williams, Richard Hafner

Get full text

Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice. by Deepak Almeida, Paul J Converse, Zahoor Ahmad, Kelly E Dooley, Eric L Nuermberger, Jacques H Grosset

Get full text

Treatment default amongst patients with tuberculosis in urban Morocco: predicting and explaining default and post-default sputum smear and drug susceptibility results. by Imad Cherkaoui, Radia Sabouni, Iraqi Ghali, Darya Kizub, Alexander C Billioux, Kenza Bennani, Jamal Eddine Bourkadi, Abderrahmane Benmamoun, Ouafae Lahlou, Rajae El Aouad, Kelly E Dooley

Get full text

Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model. by Emily A Kendall, Sourya Shrestha, Ted Cohen, Eric Nuermberger, Kelly E Dooley, Lice Gonzalez-Angulo, Gavin J Churchyard, Payam Nahid, Michael L Rich, Cathy Bansbach, Thomas Forissier, Christian Lienhardt, David W Dowdy

Get full text

Evidence Generation for a Host-Response Biosignature of Respiratory Disease by Kelly E. Dooley, Michael Morimoto, Piotr Kaszuba, Margaret Krasne, Gigi Liu, Edward Fuchs, Peter Rexelius, Jerry Swan, Krzysztof Krawiec, Kevin Hammond, Stuart C. Ray, Ryan Hafen, Andreas Schuh, Nelson L. Shasha Jumbe

Get full text

Clinical predictors of 3-month isoniazid rifapentine (3HP)-related adverse drug reactions (ADR) during tuberculosis preventive therapy (PAnDoRA-3HP study): an observational study p... by Turyahabwe Stavia, Barbara Castelnuovo, Christine Sekaggya-Wiltshire, Kelly E Dooley, Grace Banturaki, Irene Mbabazi, Ruth Mirembe Nabisere, Lucy Alinaitwe, Brian Otaalo, Florence Aber, Juliet Nampala, Rogers Owori, Josephine Bayigga, Jonathan Mayito, Eva Agnes Odongpiny Laker, Moorine Penninah Sekadde, Jotam Pasipanodya, Stella Zawedde‐Muyanja

Get full text

ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosis by Linda J. Harrison, Gustavo E. Velásquez, Russell R. Kempker, Marjorie Z. Imperial, Eric Nuermberger, Susan E. Dorman, Elisa Ignatius, Janeway Granche, Patrick P. J. Phillips, Jennifer Furin, Eunsol Yang, Colleen Foley, Shawn Chiambah, Rochelle Rogers, Austin Van Grack, Jhoanna Roa, Justin Shenje, Sandy Nerette, Cecilia Kanyama, Rachel Bakyayita Kyeyune, Alberto Mendoza-Ticona, William Murtaugh, Salah Foraida, Melanie Goth, Andrew Vernon, Kelly E. Dooley, Radojka M. Savic

Get full text

Author Correction: Risk-stratified treatment for drug-susceptible pulmonary tuberculosis by Vincent K. Chang, Marjorie Z. Imperial, Patrick P. J. Phillips, Gustavo E. Velásquez, Payam Nahid, Andrew Vernon, Ekaterina V. Kurbatova, Susan Swindells, Richard E. Chaisson, Susan E. Dorman, John L. Johnson, Marc Weiner, Amina Jindani, Thomas Harrison, Erin E. Sizemore, William Whitworth, Wendy Carr, Kia E. Bryant, Deron Burton, Kelly E. Dooley, Melissa Engle, Pheona Nsubuga, Andreas H. Diacon, Nguyen Viet Nhung, Rodney Dawson, Radojka M. Savic, AIDS Clinical Trial Group, Tuberculosis Trials Consortium

Get full text

Risk-stratified treatment for drug-susceptible pulmonary tuberculosis by Vincent K. Chang, Marjorie Z. Imperial, Patrick P. J. Phillips, Gustavo E. Velásquez, Payam Nahid, Andrew Vernon, Ekaterina V. Kurbatova, Susan Swindells, Richard E. Chaisson, Susan E. Dorman, John L. Johnson, Marc Weiner, Amina Jindani, Thomas Harrison, Erin E. Sizemore, William Whitworth, Wendy Carr, Kia E. Bryant, Deron Burton, Kelly E. Dooley, Melissa Engle, Pheona Nsubuga, Andreas H. Diacon, Nguyen Viet Nhung, Rodney Dawson, Radojka M. Savic, AIDS Clinical Trial Group, Tuberculosis Trials Consortium

Get full text